Edwards Lifesciences has received CE marking for its transfemoral transcatheter mitral valve replacement system, setting up market rivalry with Abbott. Edwards’ device, dubbed Sapien M3, is the first ...
Edwards Lifesciences’ SAPIEN M3 mitral valve replacement system has become the first transcatheter therapy utilizing a transseptal approach to snag FDA approval in the U.S. for the treatment of mitral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results